Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) filed for two new provisional patents strengthening the company’s intellectual property portfolio. The company which focuses on developing psilocybin-based medicines for illnesses with unmet medical needs announced the 2 patents via press release.
The first #63/405,786 is a patent application for the use of psilocybin to treat patients with fibromyalgia while the other patent, #63/375,305 expands the intellectual property related to the company’s development of TRP-8803.
About Tryp Therapeutics
Tryp Therapeutics is a cutting-edge biotechnology company that is focused on developing molecules related to psilocybin to treat diseases without effective medical treatments presently available with a goal to provide these treatments through accelerated regulatory pathways.
Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFN™) program is dedicated to the creation of synthetic psilocybin-related compounds as a new class of drugs for treating chronic pain, binge eating, and other indications.
Tryp Therapeutics Fibromyalgia Focused Treatment
The firm is readying for a Phase 2a clinical trial at the University of Michigan to determine the safety and preliminary efficacy of psilocybin-assisted therapy in people with fibromyalgia.
The clinical trials are expected to back up the promising preclinical findings discovered by Tryp in an animal model of nociplastic pain. Once granted, the new patent will give Tryp with Intellectual Property Protection for fibromyalgia by utilizing its psilocybin-based candidates.
Fibromyalgia is a condition that causes widespread pain and fatigue, as well as problems with sleep, memory, and mood. Existing treatments for fibromyalgia are not very effective and often have unpleasant side effects.
After one year, less than 10% of fibromyalgia patients stick to approved treatments, and around 30% of patients take opioids even though there is no evidence that they work and the known risk of addiction or overdose.
TRP-8802 & TRP-8803 Overview
Tryp is currently enrolling patients in its Phase II trial for the treatment of binge eating disorder at the University of Florida. The company also announced an upcoming Phase IIa clinical trial with the University of Michigan to evaluate TRP-8802 for fibromyalgia.
TRP-8803 is a psilocybin-based product that uses a different formulation and method of administration to improve efficacy, safety, and patient experience.
TRP-8802 is being used by Tryp to test the feasibility of utilizing psilocybin-related compounds for certain neuropsychiatric disorders. TRP-8803, which is being developed at the same time, will be studied in future trials where it indicates efficacy.
TRP-8803 is an improved version of psilocybin that overcomes the limitations of other administration routes, including oral, nasal, and sublingual.
The second provisional patent will continue to protect TRP-8803’s unique psilocybin-based drug. The primary goal of the provisional patent application is to improve the chemical properties of TRP-8803, allowing it to be more stable and suitable for use in TRP-8803’s original formulation and route of administration.